Ceritinib (LDK378)

Name: Ceritinib (LDK378)
Brand: Selleck Chemicals
SKU: S7083
Rating: 5 (76 reviews)

For research use only.

Catalog No.S7083

76 publications

CAS No. 1032900-25-6

Ceritinib (LDK378) is potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays. Ceritinib (LDK378) also inhibits IGF-1R, InsR, STK22D and FLT3 with IC50 of 8 nM, 7 nM, 23 nM and 60 nM, respectively. Phase 3.

Selleck's Ceritinib (LDK378) has been cited by 76 publications

Cell, 2021, 184(10):2649-2664.e18

PubMed: 33848463 ( click the link to review the publication )

Nature, 2019, 10.1038/s41586-019-1472-0

PubMed: 31391581 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

Clin Cancer Res, 2021, 27(9):2533-2548

PubMed: 33619172 ( click the link to review the publication )

Cell Rep, 2021, 36(7):109515

PubMed: 34407403 ( click the link to review the publication )

Cereb Cortex, 2021, bhab058

PubMed: 33791755 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):713

PubMed: 34272360 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.0221.2021

PubMed: 34158340 ( click the link to review the publication )

ESMO Open, 2021, 6(4):100172

PubMed: 34242968 ( click the link to review the publication )

Sci Rep, 2021, 11(1):9011

PubMed: 33907223 ( click the link to review the publication )

Jpn J Clin Oncol, 2021, hyab048

PubMed: 33829270 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):418

PubMed: 33841579 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Oncogene, 2020, 39(1):151-163

PubMed: 31462708 ( click the link to review the publication )

Cancers (Basel), 2020, 24;12(4) pii: E1054

PubMed: 32344689 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )
Cancer Discov, 2020, 1 pii: CD-19-1030

PubMed: 32238360 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00513-3

PubMed: 32918045 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E104

PubMed: 30658414 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Biochem J, 2019, 10.1042/BCJ20190106

PubMed: 31341009 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00802-7

PubMed: 31177400 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Blood, 2018, 131(14):1576-1586

PubMed: 29437595 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4162-4174

PubMed: 29776956 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )
Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 46(6):2487-2499

PubMed: 29742496 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):222-231

PubMed: 29054983 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):73-83

PubMed: 29133622 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Cancer Sci, 2017,

PubMed: 27783866 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1118-1125

PubMed: 29045271 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Cell Physiol Biochem, 2016, 40(5):1129-1140

PubMed: 27960155 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):601-9

PubMed: 26639656 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1118-1133

PubMed: 27432227 ( click the link to review the publication )

Sci Rep, 2016, 6:33710

PubMed: 27641368 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )
Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Mol Oncol, 2015, 10.1016/j.molonc.2015.11.007

PubMed: 26639656 ( click the link to review the publication )

Oncotarget, 2015, 6(42):44643-59

PubMed: 26556876 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 454(4):566-571

PubMed: 25450694 ( click the link to review the publication )

Purity & Quality Control

Choose Selective ALK Inhibitors

Biological Activity

Description

Features

Does not cross react with c-Met, and has an improved in vivo glucose homeostasis profile relative to TAE684. May be active in Crizotinib-relapsed tumors.

Targets

ALK ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	STK22D ^[1] (Cell-free assay)	FLT3 ^[1] (Cell-free assay)
0.2 nM	7 nM	8 nM	23 nM	60 nM

In vitro

LDK378 shows great anti-proliferative activity in Ba/F3-NPM-ALK and Karpas290 cells with IC50 of 26.0 nM and 22.8 nM, compared with IC50 of 319.5 nM and 2477 nM in Ba/F3-Tel-InsR and Ba/F3-WT cells. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Parental(+IL3)	M4Tzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX20NpBWPzJiaB?=	M2Hh[WROW09?	MYXJR\|UxRTF3OE[gxtEhOTd\|IH7N	M{LYVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5NFM1Lz5{NUe0PVA{PDxxYU6=
WT 70	M4fyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVS3NkBp	NHzlPWxFVVOR	NHS2eFBKSzVyPUKxJOKyKDhibl2=	Ml3jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEmwN\|QoRjJ3N{S5NFM1RC:jPh?=
G1128S 1022	M1O5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{[wPVczKGh?	NInnNXZFVVOR	NGPsTHpKSzVyPUGwNkDDuSB\|ODDuUS=>	M4DtZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5NFM1Lz5{NUe0PVA{PDxxYU6=
C1156F 1293	NYHJSZpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXS1bFd6PzJiaB?=	MUnEUXNQ	MXvJR\|UxRTJzNzFCtUAyOTVibl2=	MlfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEmwN\|QoRjJ3N{S5NFM1RC:jPh?=
I1171N 519	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXvIN4ZvPzJiaB?=	NX7HS2NyTE2VTx?=	M13HcGlEPTB;MUi3JOKyKDh5IH7N	NX;WfVBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFkxOzRpPkK1O\|Q6ODN2PD;hQi=>
I1171T 445	NUDIVJFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYC3NkBp	M{TDc2ROW09?	MUfJR\|UxRTh{INMxJFEzKG6P	NIqy[Xc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVA{PCd-MkW3OFkxOzR:L3G+
F1174I 184	NXHZU5gzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{jY[lczKGh?	MlSxSG1UVw>?	MkLsTWM2OD1zMzFCtUAxNjFibl2=	NXTYZmQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFkxOzRpPkK1O\|Q6ODN2PD;hQi=>
N1178H 169	MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWi3NkBp	NYKzS3J{TE2VTx?=	M3rwdWlEPTB;NEKgxtEhPiCwTR?=	MofSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEmwN\|QoRjJ3N{S5NFM1RC:jPh?=
E1210K 748	M3TsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoTBO\|IhcA>?	M4fKcmROW09?	MoLVTWM2OD1zOEegxtEhQDRibl2=	M1XzV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5NFM1Lz5{NUe0PVA{PDxxYU6=
C1156F/D1203N 2809	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2fsXFczKGh?	MVjEUXNQ	NH\zcphKSzVyPUK1OEDDuSB7OTDuUS=>	NE\3Nok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVA{PCd-MkW3OFkxOzR:L3G+
Ba/F3 NA WT	NIT2bIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{Tx[lczKGh?		MnrMTWM2OD1yLkCyNEDPxE1?	NYLkNHJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
Ba/F3 NA C1156Y	M3HzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYG3NkBp		M37pSmlEPTB;MD6wO\|Eh\|ryP	MmPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 NA L1196M	M4rjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVfLboFLPzJiaB?=		NHTjS5dKSzVyPUCuNFQzKM7:TR?=	NUnTSZg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
Ba/F3 NA L1152R	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml[1O\|IhcA>?		MYnJR\|UxRTBwMki4JO69VQ>?	M3jJblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3OFAxLz5{NUeyO\|QxODxxYU6=
Ba/F3 NA G1202R	NUn5O45YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MorIO\|IhcA>?		NVr0UoppUUN3ME2wMlI4PyEQvF2=	MkPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 NA G1269A	NXfHWHU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVi3NkBp		NFrifFZKSzVyPUCuNFE6KM7:TR?=	NEXvUVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO\|QxOCd-MkW3Nlc1ODB:L3G+
Ba/F3 NA S1206Y	MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYnWWGc2PzJiaB?=		MV3JR\|UxRTBwMEO3JO69VQ>?	MmjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 EA WT	M4TqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHeybHo4OiCq		NXj4VIMzUUN3ME2wMlAzOSEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 EA C1156Y	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{fKfVczKGh?		MkX0TWM2OD1yLkCyOkDPxE1?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 EA L1196M	M4C1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHvyd5k4OiCq		MYjJR\|UxRTBwMEG5JO69VQ>?	NYrwVZJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
Ba/F3 EA L1152R	M{niSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWLySZFwPzJiaB?=		NGXsbJlKSzVyPUCuNFk6KM7:TR?=	MonzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 EA G1202R	MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4HNV\|czKGh?		MlLETWM2OD1yLkS2O{DPxE1?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 EA G1269A	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXm3NkBp		NULzVGRmUUN3ME2wMlA{OyEQvF2=	MoLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 EA S1206Y	MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3nWOlczKGh?		NWf5eoEyUUN3ME2wMlA{QCEQvF2=	NETpSVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO\|QxOCd-MkW3Nlc1ODB:L3G+
BAF3	NY\nVZh4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEfPbmc4OiCqcoO=		NGC5RlhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGVOVDRvQVzLJIFnfGW{IEeyJIhzeyCkeTDTVmIhd3JiQ1PLPEBie3OjeTygTWM2OCB;IECuNFExPyEQvF2u	MlLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
NCI-H3122	Ml\3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NV35eFBxPzJiaILz		M37rR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIFz1cYlv\XOlZX70JGNmdGxiVnnhZoltcXS7IFHzd4F6NCCHQ{WwJF0hOC5yMUWg{txONg>?	NUnjeowyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
NCI-H2228	NIjycGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHy2PYU{KGSjeYO=		NHfSdFZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKyNlgh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IHz1cYlv\XOlZX7j[U1j[XOnZDDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gNE4xOTVizszNMi=>	M3rCZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkK3O\|I2Lz5{OU[yO\|czPTxxYU6=
SU-DHL1	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVXufnFZOyCmYYnz		M3fMT2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNWNUSKTEGgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KGy3bXnu[ZNk\W6lZT3iZZNm\CCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMD6wNVUh\|ryPLh?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ{N{eyOUc,Ojl4Mke3NlU9N2F-
DFCI114	NGC4Vo5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2LtdlczKGi{cx?=		NH\wZ\|lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTGR2kyOTRiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCJMUK2PWEhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE4xOThizszNMi=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
HCC78	MnTkR5l1d3SxeHnjbZR6KGG\|c3H5		MkTxO\|IhcHK\|		M33n[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhESzd6IHPlcIx{KGijcnLvdolv\yCVTFOzOGEzNVKRU{GgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNVgh\|ryPLh?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR5NEmyOUc,Ojd2N{S5NlU9N2F-
KARPAS299	NWHtd\|FtS3m2b4TvfIlkcXS7IHHzd4F6		NY\UPFB6OiC2bzCzJIRigXN?		MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiYX\0[ZIhOiC2bzCzJIRigXNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yMkK4JO69VS5?	M{\zT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{SyNlUzLz5{M{e0NlI2OjxxYU6=
KARPAS299	M3LrRWN6fG:2b4jpZ4l1gSCjc4PhfS=>				MoLMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2FTWEGVMkm5JINmdGy\|IHX4dJJme3OrbnegUnBONUGOSzDmeZNqd25iZ3Xu[UBie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdixiSVO1NEA:KDBwMEKyPEDPxE1w	Mny1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{e3PVcoRjJ\|OEO3O\|k4RC:jPh?=
NCI-H3122	MknKSpVv[3Srb36gZZN{[Xl?		NULhUmxEPzJiaILz		MUjJcohq[mm2aX;uJI9nKEWPTESg[pV{\WRiQVzLJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFPDOVAhRSByLkCyOUDPxE1w	NFjOSIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxOVE3QSd-Mke5NVUyPjl:L3G+
BAF3	M1Pac2Z2dmO2aX;uJIF{e2G7		NFjQZ2IzKHSxIEOg[IF6ew>?		MW\Jcohq[mm2aX;uJI9nKE6STT3meZNm\CCDTFugLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bi\nSncjCyJJRwKDNiZHH5d{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlAzPiEQvF2u	MlrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NEKyOVIoRjJ\|N{SyNlUzRC:jPh?=
BA/F3	NUnqbXV[S3m2b4TvfIlkcXS7IHHzd4F6				MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKE6STT3BUGsh\nW\|aX;uJIdmdmViYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36sJGlEPTBiPTCwMlAzPiEQvF2u	M3LEb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEO3O\|k4Lz5{M{izO\|c6PzxxYU6=
KARPAS299	NEnnUm5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnywO\|IhcHK\|		MnjWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQWLQRXMzQTliY3XscJMhcGG{Yn;ybY5oKE6STT3BUGsh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODJ4IN88UU4>	NVTYb\|hsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|Q5ODlpPkK5NVc1QDB7PD;hQi=>
NCI-H2228	MkfHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIWzcmM4OiCqcoO=		MmTyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFIzOjhiY3XscJMhcGG{Yn;ybY5oKEWPTEStRWxMKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB{NjFOwG0v	M4\2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkKzNVIxLz5\|MEKyN\|EzODxxYU6=
KARPAS299	MYDDfZRwfG:6aXPpeJkh[XO\|YYm=		NGjDO5g4OiCqcoO=		MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiaHHyZo9zcW6pIF7QUU1CVEtiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yMkeg{txONg>?	MkPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2N{S5NlUoRjJ5NEe0PVI2RC:jPh?=
Ba/F3	NGG4b2dHfW6ldHnvckBie3OjeR?=		MkH5O\|IhcHK\|		MmntTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCVMUKwOnkhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjB\|MzFOwG0v	MnzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
NCI-H3122	MnftRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				M4PtXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJIh2dWGwIF7DTU1JOzF{MjDj[YxteyxiQ1O1NEA:KDBwMEO4JO69VS5?	NGTES4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzOVk1PSd-Mk[yN\|U6PDV:L3G+
NCI-H3122	Mnj3SpVv[3Srb36gZZN{[Xl?		MWO3NkBpenN?		MkTxTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhS0N3MDC9JFAvODN6IN88UU4>	NY\vToNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5NlM3QTVpPkK2PVI{Pjl3PD;hQi=>
NCI-H3122	NIDrUndHfW6ldHnvckBie3OjeR?=		NIPtUGg4OiCqcoO=		MXPJcohq[mm2aX;uJI9nKEWPTEStRWxMKGmwIHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBESzVyIE2gNE4xOzhizszNMi=>	Mnr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7MkO2PVUoRjJ4OUKzOlk2RC:jPh?=
NCI-H3122	MmDHSpVv[3Srb36gZZN{[Xl?		M1foc\|czKGi{cx?=		NUOxRWlNUW6qaXLpeIlwdiCxZjDFUWw1KG[3c3XkJGFNUyCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBESzVyIE2gNE4xOzhizszNMi=>	NHqxdZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO4OVUxPSd-MkizPFU2ODV:L3G+
BA/F3	MlnoSpVv[3Srb36gZZN{[Xl?				NEe4cplKdmirYnn0bY9vKG:oIFHMT{ApfW6tbn;3ckBwemmpaX6pJJRz[W6\|ZnXjeIVlKGmwIH3veZNmKEKDL1[zJINmdGy\|LDDJR\|UxKD1iMD6wOFA4KM7:TT6=	NVTGTGZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4N\|c4QTdpPkKzPFM4Pzl5PD;hQi=>
Ba/F3	M4HLWWZ2dmO2aX;uJIF{e2G7		M3PT[lczKGi{cx?=		Ml7zTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE1CVEtiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQnGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IECuNFQyKM7:TT6=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Ba/F3	MX7GeY5kfGmxbjDhd5NigQ>?		NHzKXVM4OiCqcoO=		Ml[2TY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE1CVEtiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQnGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IECuNFQyKM7:TT6=	NG\aOlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
KARPAS299	Mm\5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFfD[Xo4OiCqcoO=		M3KzcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB2MTFOwG0v	M4nvVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkKzNVIxLz5\|MEKyN\|EzODxxYU6=
BAF3	NILteJVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVWw[HBYPzJiaILz		MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIFyxNVk3VSCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4xPTR7IN88UU4>	MlX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
Ba/F3	MlzjSpVv[3Srb36gZZN{[Xl?		NH7Y[4E4OiCqcoO=		MofBTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCJMUK2PWEhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjB3NzFOwG0v	NHHqWpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
HCC78	NYHaNlhNSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mmq1O\|IhcHK\|		MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFQ{e4JINmdGy\|IHjhdoJwemmwZzDTUGM{PEF{LWLPV\|Eh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODV6IN88UU4>	NFe0e4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgxQSd-MkmxO\|Q5ODl:L3G+
HCC78	Mm\yRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{CzcFczKGi{cx?=		NIL2dI1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|c5KGOnbHzzJIhiemKxcnnu[{BUVEN\|NFGyMXJQWzFiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEW4JO69VS5?	M1jtOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkKzNVIxLz5\|MEKyN\|EzODxxYU6=
Ba/F3	MV7GeY5kfGmxbjDhd5NigQ>?		NHz4UoQ4OiCqcoO=		NFjYO4pKdmirYnn0bY9vKG:oIFXNUFQuSUyNIFyxNVk3VSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwME[0JO69VS5?	MmPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
DFCI76	NHrK[2VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXHlbFllPzJiaILz		MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESIQ1m3OkBk\WyuczDlfJBz\XO\|aX7nJGVOVDRvQVzLJGwyOTV{UjDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkC3NkDPxE1w	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
BAF3	MnjzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiZYjwdoV{e2mwZzDBUGshVDFzOU\NJI12fGGwdDygR2M2OCB;IECuNFc2KM7:TT6=	NHvMUVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzOVk1PSd-Mk[yN\|U6PDV:L3G+
BA/F3	NEjIOGZHfW6ldHnvckBie3OjeR?=		M1HQblczKGi{cx?=		MmjCTY5pcWKrdHnvckBw\iCDTFugUFEyQT[PIH31eIFvfCCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliV2PUNUBie3OjeTygR2M2OCB;IECuNFc2KM7:TT6=	NUDjTlBnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5NlM3QTVpPkK2PVI{Pjl3PD;hQi=>
BA/F3	M{XHZWZ2dmO2aX;uJIF{e2G7		MkD1O\|IhcHK\|		MnTHTY5pcWKrdHnvckBw\iCHTVy0JIZ2e2WmIFHMT{BNOTF7Nl2gcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygR2M2OCB;IECuNFc2KM7:TT6=	NVHFZm1{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVUyPjlpPkK3PVE2OTZ7PD;hQi=>
BA/F3	MYHGeY5kfGmxbjDhd5NigQ>?		NETqTlc4OiCqcoO=		NH:1PFZKdmirYnn0bY9vKG:oIFXNUFQh\nW\|ZXSgRWxMKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25ibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiQ1O1NEA:KDBwMEe1JO69VS5?	M1[1dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUG1NVY6Lz5{N{mxOVE3QTxxYU6=
BAF3	M1TtXGZ2dmO2aX;uJIF{e2G7		Ml33O\|IhcHK\|		Mmi0TY5pcWKrdHnvckBw\iCDTFugUFEyQT[PIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFeVVD2xJIF{e2G7LDDDR\|UxKD1iMD6wO\|Uh\|ryPLh?=	NV76WZdRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizPFU2ODVpPkK4N\|g2PTB3PD;hQi=>
KARPAS299	Mnz3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWO3NkBpenN?		NHntNGJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCqYYLic5JqdmdiTmDNMWFNUyCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjB6NDFOwG0v	NWTHO4t1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
SMS-KCNR	NVrHXllTSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NILhfmQ4OiCqcoO=		MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOPUz3LR25TKGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshWjF{N{XRJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuNFkzKM7:TT6=	NGq3cWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
NCI-H3122	M3vEVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MmnNO\|IhcHK\|		NFWyR\|dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzF{MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjB7NjFOwG0v	Mn3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
NCI-H2228	Mn7rRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NUjqOW1QPzJiaILz		MmWwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFIzOjhiY3XscJMhcGG{Yn;ybY5oKEWPTEStRWxMKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB7OTFOwG0v	NEP1NG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgxQSd-MkmxO\|Q5ODl:L3G+
Ba/F3	NGD2bHRHfW6ldHnvckBie3OjeR?=		MV:3NkBpenN?		NFXBNohKdmirYnn0bY9vKG:oIFXNUFQuSUyNIF[xNVc1VCCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMUCxJO69VS5?	NWTEUVRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
NCI-H2228	NYjjUGhYS3m2b4TvfIlkcXS7IHHzd4F6		NILMO4I4OiCqcoO=		NEXqXmhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEKyNlgh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IECuNVAzPiEQvF2u	NXHwfVJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFQ3PzFpPkK1OlQ1PjdzPD;hQi=>
LAN5	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIj4cGg4OiCqcoO=		NEi0SHZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzBUlUh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BTOTJ5NWGgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6xNlIh\|ryPLh?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
SU-DHL1	MnznRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHe2RXc4OiCqcoO=		MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOXLVTIUFEh[2WubIOgbIFz[m:{aX7nJG5RVS2DTFugZYZ1\XJiN{KgbJJ{KGK7IGPSRkBweiCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6xNlIh\|ryPLh?=	M3jkdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Kelly	NXP1VYs1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYC3NkBpenN?		MkLuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNZXzsfUBk\WyuczDlfJBz\XO\|aX7nJGVOVDRvQVzLJGYyOTd2TDDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkG0NkDPxE1w	M{TpN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Ba/F3	MYDGeY5kfGmxbjDhd5NigQ>?		M1KwPFczKGi{cx?=		MYTJcohq[mm2aX;uJI9nKEWPTEStRWxMKENzMUW2XUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvOTZ2IN88UU4>	M2C4b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
SH-SY5Y	NVHqbmlRSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1PQelczKGi{cx?=		NGTIeFJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPIMXN[PVliY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCIMUG3OGwhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE4yQDZizszNMi=>	NGOxbmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
BAF3	NFzKbJBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NUO4W4V2PzJiaILz		NXXTWXd{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BETDd2LWLPV\|Eh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4zOzRizszNMi=>	MlfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
SK-N-SH	M37G[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1:3VVczKGi{cx?=		Mn\ORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSz3OMXNJKGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshTjFzN{TMJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuN\|A{KM7:TT6=	M3TodFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
BAF3	M3HkW2Z2dmO2aX;uJIF{e2G7		MWKyJJRwKDNiZHH5dy=>		NI\afFdKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZYZ1\XJiMjD0c{A{KGSjeYOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6zNVk2KM7:TT6=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2MkK1Nkc,OjN5NEKyOVI9N2F-
BA/F3	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=				MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJHRmdC2LboPSJIdmdmViYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36sJGlEPTBiPTCwMlMzKM7:TT6=	NFLPS2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izO\|c6Pyd-MkO4N\|c4QTd:L3G+
SK-N-FI	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFrTRlA4OiCqcoO=		NUTHSWJRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNU[LIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6zOFkh\|ryPLh?=	MkPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
CHLA20	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MoDjO\|IhcHK\|		MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOKTFGyNEBk\WyuczDlfJBz\XO\|aX7nJGVOVDRvQVzLJHIyOjd3UTDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkO2N{DPxE1w	M1LKclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Ba/F3	NH2xVZJHfW6ldHnvckBie3OjeR?=		MWq3NkBpenN?		MVjJcohq[mm2aX;uJI9nKEWPTEStRWxMKEdzMkCyVkBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvPDR2IN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
LAN1	NEnZW3VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MY[3NkBpenN?		MlrIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOQV6xJINmdGy\|IHX4dJJme3OrbnegSW1NPC2DTFugSlEyPzSOIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW\|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDBwNUS5JO69VS5?	MoGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
SK-N-BE(2)	NEPaZllCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4\BWlczKGi{cx?=		MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV6tRmUpOiliY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRV3MOE1CVEtiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkW5N{DPxE1w	NXjKWFhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Ba/F3	Mnj1SpVv[3Srb36gZZN{[Xl?		MW[3NkBpenN?		NXG4PYRoUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzCxNVUyXGmwczDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQnGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IECuOlY5KM7:TT6=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
BAF3	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1HadlczKGi{cx?=		MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIFexNlAzWiCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE44OjZizszNMi=>	NG\OeHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Ba/F3	NF2zSlVHfW6ldHnvckBie3OjeR?=		M2fsWFczKGi{cx?=		NHu2dYtKdmirYnn0bY9vKG:oIHj1cYFvKEWJRmKg[IVtOTlxVEe5NG0wSzd7N2OgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE44QDB3IN88UU4>	MnLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzM{[0OlUoRjJ7MUO2OFY2RC:jPh?=
SK-N-AS	MmTTRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mn;TO\|IhcHK\|		Mn7XRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSz3OMWFUKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWPTEStRWxMKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIFz1cYlv\XOlZX70JGNmdGxiVnnhZoltcXS7IFHzd4F6NCCHQ{WwJF0hOS5yNEWg{txONg>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
BAF3	M{X5[GN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mk\xNkB1dyB\|IHThfZM>		MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIFnfGW{IEKgeI8hOyCmYYnzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IEKuOFc4KM7:TT6=	NIf4[Gs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0NlI2Oid-MkO3OFIzPTJ:L3G+
Ba/F3	MYHGeY5kfGmxbjDhd5NigQ>?		NEm3Rlk4OiCqcoO=		MVzJcohq[mm2aX;uJI9nKEWPTEStRWxMKExzMUWyVkBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFIvPzR5IN88UU4>	NH:wTZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
BA/F3	NYH6Omc4S3m2b4TvfIlkcXS7IHHzd4F6		MUK3NkBpenN?		MmLMR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFUvPTF{IN88UU4>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
KARPAS299	NHXNWJpCeG:ydH;zbZMh[XO\|YYm=	M{P5cVYxKG6P	MV[yOEBpenN?		NEfaW3VKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCqYYLic5JqdmdiTmDNMWFNUyCjdDC2NEBvVSCjZoTldkAzPCCqcoOgZpkh[WO{aXTpcoUhd3KjbnflM4V1cGmmaYXtJIJzd22rZHWgd5RicW6rbnegZoF{\WRiZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKG2ndHjv[C=>	NHrIclM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgxQSd-MkmxO\|Q5ODl:L3G+
SU-DHL1	MWPGeY5kfGmxbjDhd5NigQ>?	NH3o[mQzOCC2bzCyNFAhdk1?	MWexJIhz		MnTHTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHH0JHk4ODVicnXzbYR2\SCjdDCyNEB1dyB{MECgcm0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NF23VWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
SU-DHL1	Mlf6SpVv[3Srb36gZZN{[Xl?	MmDmNlAhfG9iMkCwJI5O	MnvpNUBpeg>?		M1z5RWlvcGmkaYTpc44hd2ZiQVzLJJBpd3OyaH;yfYxifGmxbjDheEB[OTJ5ODDy[ZNq\HWnIHnuJIh2dWGwIGPVMWRJVDFiY3XscJMh[XRiMkCgeI8hOjByIH7NJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NFrscJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
NCI-H3122	NF7FOZZHfW6ldHnvckBie3OjeR?=	Mn:1NlAhfG9iMkCwJI5O	NUjjOpg4OSCqch?=		M{fucmlvcGmkaYTpc44hd2ZiQVzLJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRWLLJJBpd3OyaH;yfYxifGmxbjDheEBVOjB{Lz;ZNlA1KHKnc3nkeYV{KGG2IEKwJJRwKDJyMDDuUUBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
NCI-H3122	NIf6SWZHfW6ldHnvckBie3OjeR?=	Ml\iNlAhfG9iMkCwJI5O	NFTpRZgyKGi{		NE\a[FNKdmirYnn0bY9vKG:oIFHMT{BqdiCqdX3hckBPS0lvSEOxNlIh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFHreEBxcG:\|cHjvdplt[XSrb36gZZQhWzR5MzDy[ZNq\HWnIHH0JFIxKHSxIEKwNEBvVSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NGLxdYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
SU-DHL1	MnHmSpVv[3Srb36gZZN{[Xl?	NXrvSXl7OjBidH:gNlAxKG6P	NEXIepUyKGi{		NXjrRoplUW6qaXLpeIlwdiCxZjDBUGshcW5iaIXtZY4hW1VvRFjMNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iQXv0JJBpd3OyaH;yfYxifGmxbjDheEBUPDd\|IILld4llfWViYYSgNlAhfG9iMkCwJI5OKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
SU-DHL1	NWPKR29nTnWwY4Tpc44h[XO\|YYm=	M1HpWVIxKHSxIEKwNEBvVQ>?	M2LF[VEhcHJ?		MmDQTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNIIDoc5NxcG:{eXzheIlwdiCjdDDUNlAzNy:\MkC0JJJme2mmdXXzJIF1KDJyIITvJFIxOCCwTTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
NCI-H3122	NGjhcJZHfW6ldHnvckBie3OjeR?=	Mn\ENlAhfG9iMkCwJI5O	NWP3OpdzOSCqch?=		MUfJcohq[mm2aX;uJI9nKEGOSzDwbI9{eGixconsZZRqd25iYYSgXVEzPzhicnXzbYR2\SCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[XRiMkCgeI8hOjByIH7NJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MmnSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
NCI-H3122	M1zsO2Z2dmO2aX;uJIF{e2G7	M1rRWFIxKHSxIEKwNEBvVQ>?	NIDLW\|YyKGi{		NWC2NmVuUW6qaXLpeIlwdiCxZjDBUGshcW5iaIXtZY4hVkOLLVizNVIzKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiWUewOUBz\XOrZIXlJIF1KDJyIITvJFIxOCCwTTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NGTxco89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
SU-DHL1	MkXkSpVv[3Srb36gZZN{[Xl?	M2W3OFMxKG6P	NYjvcYNGOTZiaILz		NHv1eFRKdmirYnn0bY9vKG:oIFHMT{BifXSxcHjvd5Bpd3K7bHH0bY9vKGG2IGmxOVA4KHKnc3nkeYUhcW5iaIXtZY4hW1VvRFjMNUBk\WyuczDheEA{OCCwTTDh[pRmeiBzNjDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	M13UNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkK3O\|I2Lz5{OU[yO\|czPTxxYU6=
SU-DHL1	NX25eXpOTnWwY4Tpc44h[XO\|YYm=	MWOzNEBvVQ>?	Mmf1NVYhcHK\|		M{fJemlvcGmkaYTpc44hd2ZiQVzLJIlvKGi3bXHuJHNWNUSKTEGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEB[PzB3IILld4llfWViYYSgN\|Ahdk1iYX\0[ZIhOTZiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NX;ndI1zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2Nlc4OjVpPkK5OlI4PzJ3PD;hQi=>
NCI-H3122	M37qdWZ2dmO2aX;uJIF{e2G7	MUi1NEB1dyB{NUCgcm0>	M13FblE3KGi{cx?=		NESzR2RKdmS3Y4Tpc44hd2ZiQVzLJIRm\3KjZHH0bY9vKGmwIHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDBUGsheGixc4Doc5J6dGG2aX;uJIF1KFlzNkC0JIF1KDVyIITvJFI2OCCwTTDh[pRmeiBzNjDodpMh[nliaX3teY5w[myxdDDt[ZRpd2R?	MkHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NkC5PFQoRjJ7Nk[wPVg1RC:jPh?=
SH-SY5Y	NWfnSZlWSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnfkO\|IhcHK\|		MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOKLWPZOXkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYm=	M17QRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Nk[wPVg1Lz5{OU[2NFk5PDxxYU6=
CHLA20	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFfKVZo4OiCqcoO=		M3yxNGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1jMRVIxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG\|c3H5	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ4MEm4OEc,Ojl4NkC5PFQ9N2F-
SH-SY5Y	M1faU2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHS3Uo44OiCqcoO=		M4LheGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1itV3k2YSClZXzsd{Bi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhSUKFQkGgbY5pcWKrdH;yJJRiemmzdXnkZZIh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeR?=	Ml:yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NkC5PFQoRjJ7Nk[wPVg1RC:jPh?=
KARPAS299	M1HueGZ2dmO2aX;uJIF{e2G7	M3LUb\|UxKHSxIEK1NEBvVQ>?	MkXVNVYhcHK\|		NV;SOpY6UW6mdXP0bY9vKG:oIFHMT{Bl\We{YXTheIlwdiCrbjDoeY1idiCNQWLQRXMzQTliY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gRWxMKHCqb4PwbI9zgWyjdHnvckBifCC\MU[wOEBifCB3MDD0c{AzPTBibl2gZYZ1\XJiMU[gbJJ{KGK7IHntcZVvd2Kub4SgcYV1cG:m	M172VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Nk[wPVg1Lz5{OU[2NFk5PDxxYU6=
CHLA20	NELKXmhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1;M[lczKGi{cx?=		MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOKTFGyNEBk\WyuczDh[pRmeiB5MjDodpMhcW5icILld4Vv[2Vib3[gRWJESjFiaX7obYJqfG:{IIThdolyfWmmYYKgZpkhS2WubGTpeIVzNUeubzDseY1qdmW\|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigQ>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ4MEm4OEc,Ojl4NkC5PFQ9N2F-
NCI-H3122	NEHzZo5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnzWO\|IhcHK\|		NVTl[ZN5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[Xl?	M1jtcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Nk[wPVg1Lz5{OU[2NFk5PDxxYU6=
KARPAS299	M1vZU2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4LMN\|czKGi{cx?=		NGfEc25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDseY1qdmW\|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigQ>?	NWHjPIQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OlA6QDRpPkK5OlYxQTh2PD;hQi=>
SU-DHL1	MnzSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEP1cJk4OiCqcoO=		NGC2SIRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPVMWRJVDFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZk>	MoLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NkC5PFQoRjJ7Nk[wPVg1RC:jPh?=
KARPAS299	MYHBdI9xfG:\|aYOgZZN{[Xl?	M{LwV\|UxKG6P	MkTYNlQhcHK\|		NXLKeIcxUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiYYPz[ZN{\WRiYYOgeY5kdGWjcjDj[YxtKHOqcnnub4Fo\SCjdDC1NEBvVSCjZoTldkAzPCCqcoOgZpkhUG:nY3jzeEA{OzJ3ODDzeIFqdmmwZzDiZZNm\CCrbo\ldpRm\CCobIXvdoV{[2WwY3WgcYlkem:\|Y3;wfS=>	NHjweIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKyN\|EzOCd-M{CyNlMyOjB:L3G+
KARPAS299	MUnBdI9xfG:\|aYOgZZN{[Xl?	NWXTZo5jPTBibl2=	MUmyOEBpenN?		M4n3S2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHzheIUh[XCxcITveIlkKGOnbHzzJIF1KDVyIH7NJIFnfGW{IEK0JIhzeyCkeTDBU{9GSiCmb4XicIUhe3SjaX7pcoch[mG\|ZXSgbY53\XK2ZXSg[ox2d3Knc3PlcoNmKG2rY4Lvd4NweHl?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ{M{GyNEc,OzB{MkOxNlA9N2F-
KARPAS299	NGjaVGhCeG:ydH;zbZMh[XO\|YYm=	M3;OOVUxKG6P	NFvsSmYzPCCqcoO=		MWTJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bie3Onc4Pl[EBieyCocnHncYVvfGG2aX;uJIF1KDVyIH7NJIFnfGW{IEK0JIhzeyCkeTDIc4VkcHO2IEOzNlU5KHO2YXnubY5oKGKjc3XkJIlvfmW{dHXkJIZtfW:{ZYPj[Y5k\SCvaXPyc5Nkd3C7	NYniOI1FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ALK / ALK / p-AKT / AKT / p-ERK / ERK; PubMed: 28425916 eLife Inhibition of ALK autophosphorylation and downstream signaling by ceritinib, crizotinib and PF06463922 in NB-1 cells. Cells were harvested after treatment for 4 hr with the indicated compounds at different concentrations. Whole cell lysates were analyzed by Western blotting to detect the levels of ALK, AKT and ERK proteins and their phosphorylation. pROS1 / ROS1 / pSTAT3 / STAT3 ; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.	28425916 25351743
Growth inhibition assay	Cell viability; PubMed: 29067644 Target Oncol The effects of ceritinib treatment on cell viability in ARMS and ERMS cell lines. Cells were treated with 0-5 μM ceritinib for 72 h (Rh30, RD), 120 h (Rh41), or 144 h (Rh18, Aska) and cell viability was assessed. The y-axis represents relative cell viability compared to non-treated cells (control). Effects on cell viability were determined in triplicate. Values are presented as mean ± SD. Dotted line represents the IC50-value. The human synovial sarcoma cell line Aska with constitutive ALK phosphorylation was used as a positive control.	29067644

In vivo

LDK378 is designed to reduce the possibility of forming reactive metabolites and shows undetectable levels of glutathione (GSH) adducts (<1%) in liver microsomes. LDK378 has relatively good metabolic stability, with moderate CYP3A4 (Midazolam substrate) inhibition and hERG inhibition. LDK378 exhibits low plasma clearance in animals (mouse, rat, dog and monkey) compared to liver blood flow, with the oral bioavailability of above 55% in mouse, rat, dog and monkey. LDK378 induces a dose-dependent growth inhibition and tumor regression in the Karpas299 and H2228 rat xenograft models, with no body-weight loss. LDK378 shows no impact on insulin levels or plasma glucose utilization in the mouse upon chronic dosing up to 100 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Enzymatic kinase profiling description: All kinases are expressed as either Histidine- or GST-tagged fusion proteins using the baculovirus expression technology except for the untagged ERK2 which is produced in E. coli. The kinase activity is measured in the LabChip mobility shift assay. The assay is performed at 30°C for 60 min. The effect of LDK378 on the enzymatic activity is obtained from the linear progress curves in the absence and presence of LDK378 and routinely determines from one reading (end point measurement)
Cell Research:^[1]	- Collapse Cell lines: Ba/F3-NPM-ALK, Ba/F3-Tel-InsR, Ba/F3-WT, Karpas299 cells Concentrations: ~100 μM Incubation Time: 2-3 days Method: Luciferase-expressing cells are incubated with serial dilutions of LDK378 or DMSO for 2-3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: RNU nude rats bearing the Karpas299/H2228 tumors Dosages: ~50 mg/kg Administration: Oral gavage (Only for Reference)

References

[1] Marsilje TH, et al. J Med Chem. 2013, Jun 6.

Solubility (25°C)

In vitro	DMSO	20 mg/mL warmed (35.83 mM)
	Ethanol	3 mg/mL (5.37 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ceritinib (LDK378) SDF

Molecular Weight	558.14
Formula	C₂₈H₃₆ClN₅O₃S
CAS No.	1032900-25-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02450903	Completed	Drug: LDK378	Non-Small-Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	August 21 2015	Phase 2
NCT02040870	Completed	Drug: LDK378	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	March 7 2014	Phase 1\|Phase 2
NCT01950481	Completed	Drug: LDK378	Normal Hepatic Function\|Impaired Hepatic Function	Novartis Pharmaceuticals\|Novartis	January 2014	Phase 1
NCT01772797	Completed	Drug: LDK378\|Drug: AUY922	Anaplastic Lymphoma Kinase (ALK)\|Non-small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	June 2013	Phase 1
NCT01685060	Completed	Drug: LDK378	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	November 26 2012	Phase 2
NCT01634763	Completed	Drug: LDK378	Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)	Novartis Pharmaceuticals\|Novartis	June 2012	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
how to reconstitute the inhibitor for oral administration to mice?
Answer:
You can resuspend LDK378 in 30% PEG400/0.5% Tween 80/5% propylene glycol and use the suspension for oral gavage feeding.

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

Non-specific ALK Inhibitor

GSK1838705A : IGF-1R, IC50=2.0 nM; IR, IC50=1.6 nM, ALK, IC50=0.5 nM.
FDA-approved ALK Inhibitor

Crizotinib (PF-02341066) : Approved by FDA for non-small cell lung carcinoma (NSCLC).
Newest ALK Inhibitor

ASP3026 ^New : Novel and selective inhibitor for ALK with IC50 of 3.5 nM.
Classic ALK Inhibitor

TAE684 (NVP-TAE684) : Potent and selective ALK inhibitor with IC50 of 3 nM, 100-fold more sensitive for ALK than InsR.

Related ALK Products

Lorlatinib (PF-6463922) ^New

Lorlatinib (PF-6463922) is a potent, dual ALK/ROS1 inhibitor with K_i of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. PF-06463922 induces apoptosis. Phase 1.
Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
TAE684 (NVP-TAE684)

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR. TAE684 (NVP-TAE684) induces cell cycle arrest and apoptosis.
GSK1838705A

GSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases.

Features:A small-molecule kinase inhibitor of IGF-1R and the insulin receptor.
Alectinib (CH5424802)

Alectinib (CH5424802, AF-802, RG-7853) is a potent ALK inhibitor with IC50 of 1.9 nM in cell-free assays, sensitive to L1196M mutation and higher selectivity for ALK than PF-02341066, NVP-TAE684 and PHA-E429.
ASP3026

ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. Phase 1.
AZD3463

AZD3463 is a novel orally bioavailable ALK inhibitor with K_i of 0.75 nM, which also inhibits IGF1R with equivalent potency. AZD3463 suppresses cell viability by inducing both cell apoptosis and autophagy.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Ceritinib (LDK378)